Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
129 hedge funds and large institutions have $973M invested in Apellis Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 12 closing their positions.
1,855% more call options, than puts
Call options by funds: $9.03M | Put options by funds: $462K
258% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 12
61% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 28
30% more funds holding
Funds holding: 99 → 129 (+30)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.6% less ownership
Funds ownership: 64% → 63.4% (-0.6%)
5% less capital invested
Capital invested by funds: $1.03B → $973M (-$52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$57.8M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$30.2M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$19.3M |
| 4 |
Millennium Management
New York
|
+$18.4M |
| 5 |
Morgan Stanley
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.7M |
| 2 |
O
OrbiMed
New York
|
-$33M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16.3M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$13.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.2M |
APLS Hedge Fund Activity: Q3 2019 in Review
129 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2019, worth a combined $973M — down 5.1% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new APLS positions and 12 closed out — a net gain of 31 holders — while 45 added to existing stakes and 28 trimmed.
The largest buyer was HHLR Advisors, adding an estimated $57.8M. The largest seller was Wellington Management Group, cutting an estimated $41.7M.
- 129 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2019, up from 99 in Q2 2019.
- Funds reported $973M of Apellis Pharmaceuticals stock for Q3 2019, down 5.1% quarter-over-quarter.
- 43 funds opened new Apellis Pharmaceuticals positions in Q3 2019 and 12 closed out, a net change of +31 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2019 was HHLR Advisors, an estimated $57.8M added.
- The largest Apellis Pharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $41.7M sold.
Based on aggregated 13F filings for Q3 2019.